PLASMA PROTEIN THERAPEUTICS ASSOCIATION

Lobbying for PLASMA PROTEIN THERAPEUTICS ASSOCIATION

Filing 1st Quarter - Amendment

Reporting period

1st Quarter 2026

Jan 1 - Mar 31 · Posted May 19, 2026

Expenses

$160,000.00

What this organization spent lobbying with its own staff. Reported using A: the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.

Client based in

Maryland

Official filing document

Government bodies contacted 10

Centers For Disease Control & Prevention (CDC)
Centers For Medicare and Medicaid Services (CMS)
Commerce, Dept of (DOC)
Food & Drug Administration (FDA)
Health & Human Services, Dept of (HHS)
Homeland Security, Dept of (DHS)
HOUSE OF REPRESENTATIVES
SENATE
State, Dept of (DOS)
U.S. Trade Representative (USTR)

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when.

Lobbying activity 3

Medicare/Medicaid

Medicare Part B provisions relating to home infusion of IVIG. CMS programs relating to reference pricing systems. Issues relating to Source plasma donation and plasma protein products. Pricing proposals such as reference pricing/Most Favored Nations as they relate to access to plasma derived therapies.

Health Issues

Education visits to House and Senate offices relating to plasma protein therapies and the rare disease patients that use them, and the need for continued Source plasma donations. Medicare Part B provisions relating to home infusion of IVIG, particularly in CIPD and Alpha 1. CMS programs relating to reference pricing systems. Inflation Reduction Act and negotiation provisions for plasma derived therapies.

Trade (domestic/foreign)

Issues relating to tariffs and the importation of plasma-derived medicines, plasma intermediates, and materials necessary to collect source plasma donations and manufacture plasma derived-medicines.

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.